Participated · Equity · Mar 2024

WeKall offers voice and messaging software powered by AI, including business telephony, a cloud contact center and virtual assistants, with integrations such as HubSpot, Microsoft Teams and Zendesk. Its AI analyzes sentiment, identifies keywords and tracks sales and customer-service scripts to turn conversations into actionable insights. The company was founded in 2018 in Cali by brothers Felipe and Julian Sanchez and is positioned as a challenger to incumbents like Avaya. Management says the product improves customer satisfaction and sophisticates the telesales channel. WeKall is pursuing international expansion, with explicit plans to grow into Mexico. The recent investment aims to support that growth and acceleration of its commercial presence in Spanish-speaking markets.

Led · Series A · Sep 2022

Alitheon develops FeaturePrint, an optical-AI system that captures unique surface details of physical objects to create immutable digital identities without tags, labels, or stickers. The company positions FeaturePrint as a 1-to-1 serialization method that enables provenance, anti-counterfeiting, and zero-trust verification across industries from industrial parts to healthcare and luxury goods. Alitheon holds more than 55 issued patents around its technology. The firm says its solution links physical items to digital records via standard camera scans, eliminating external markers that can be damaged or spoofed. Alitheon is headquartered in Bellevue, Wash., and the company plans to use newly raised capital to accelerate global deployment of its technology. Financially, the most recent disclosed funding is the $8 million Series A1 announced in June 2026, with participation from Emerald Technology Ventures, eBay Ventures, and existing investors.

Participated · Series C · Jul 2020

LumiThera is a Seattle-based commercial-stage medical device company developing the Valeda Light Delivery System, a multi-wavelength photobiomodulation (PBM) treatment for ocular disorders including dry age-related macular degeneration (AMD) and diabetic retinopathy. The company has been granted CE Mark authorization for Valeda in the European Economic Area, but Valeda is not approved by the U.S. Food & Drug Administration. LumiThera is completing enrollment in two prospective, randomized, double-masked clinical trials: LIGHTSITE II in Europe and LIGHTSITE III in the U.S., and is planning additional trials for diabetic macular edema and AMD. It raised approximately $14M in a Series C financing. The company intends to use the proceeds to commercialize Valeda, complete LIGHTSITE III enrollment, and pursue U.S. regulatory clearance. Led by President and CEO Clark Tedford, Ph.D., LumiThera focuses on office-based PBM treatments delivered by eye care specialists. LumiThera is a Seattle-based clinical-stage medical device company developing non-invasive photobiomodulation (PBM) treatments for ocular disorders using light-emitting diodes. Its lead product is the LT-300, an ophthalmologist LED office-based instrument being developed to treat dry age-related macular degeneration (AMD). The company is conducting the LIGHTSITE I study, a prospective, randomized, double-masked clinical trial in 30 dry AMD subjects using the LT-300 light delivery system. LumiThera plans to use recently raised funds to further develop the LT-300, pursue regulatory clearances in select countries outside the USA including the CE mark in Europe, and expand clinical and commercial activities. The company completed a $5.5M Series B round led by WaterStone Capital with participation from RPR Venture. Clark Tedford, Ph.D., serves as President and CEO.